Publish time: 2022-06-28 00:00:00
28A-1100916
US provisional
The 5SB12, 1-2SA8 and 15SE6 monoclonal antibodies identified here were isolated from peripheral blood of convalescent COVID-19 patients by single B cell screening platform and recombinant antibody technology. 1-2SA8 and 15SE6 possess neutralizing activity against various variants of SARS-CoV-2 pseudoviruses, and prophylactic efficacy against SARS-CoV-2 infection in hamsters. 5SB12 does not possess strong neutralizing activity against SARS-CoV-2, but exhibits ADCC activity when engaging with NK cells, and shows prophylactic efficacy against SARS-CoV-2 infection in hamsters
- mAbs bind with Spike protein with high avidity: 1-2SA8 and 15SE6 bind with RBD domain of various Spike variants, neutralize various SARS-CoV-2 variant pseudoviruses and protect hamsters from SARS-CoV-2 infection.
- mAb utilizes ADCC activity to provide protective efficacy: 5SB12 possesses ADCC activity and protects hamsters from SARS-CoV-2 infection.
SARS-CoV-2 detection/diagnosis: 5SB12, 1-2SA8 and 15SE6 human mAbs can bind with Spike protein of various SARS-CoV-2 variants.
SARS-CoV-2 therapy: 1-2SA8 and 15SE6 human mAbs show neutralizing activity against various SARS-CoV-2 pseudovirus variants, and prophylactic efficacy against SARS-CoV-2 infection in hamsters. 5SB12 human mAb provides ADCC activity and prophylactic efficacy against SARS-CoV-2 infection in hamsters.
Kuo-I Lin, Takashi Angata, Yi-Hsuan Chang, Wei-Nan Chen, Szu Teng Ma
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Human monoclonal antibodies possess protective efficacy against various SARS-CoV-2 variants